FindMyKOL
Clinical trialNCT05020678Active, not recruitingPhase 1Interventional

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

SponsorNkarta, Inc.Enrollment150Aggressive LymphomaB-cell Acute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaIndolent LymphomaLarge B-cell LymphomaLarge-cell Lymphoma+4 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL)
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia
  • Institute of Haematology, Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • St. Vincent'S Hospital

    Sydney, New South Wales, Australia

  • Royal Brisbane and Woman'S Hospital

    Brisbane, Queensland, Australia

  • Peter Maccallum Cancer Center

    Melbourne, Victoria, Australia

United States
  • Colorado Blood Cancer Institute

    Denver, Colorado, United States

  • the Cleveland Clinic Foundation

    Cleveland, Ohio, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

NKX019
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
20 Aug 2021
Primary completion
31 Mar 2025
Completion
31 Dec 2038
Last update posted
20 Apr 2026
Registered enrollment
150
Registry id
NCT05020678
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.